Pub Date : 2017-08-03DOI: 10.4172/2376-0419.1000E145
N. Ibrahim
The essential feature of the immune system is the ability to recognize and differentiate any foreign body or abnormal cells such as tumor cells from normal cells. Tumor cells produce tumor antigens which activate the immune system. These antigens attract immune cells to the tumor site where they invade and attack. Accordingly, the immune system recognizes the tumor cells and targets them for elimination.
{"title":"Immuno-Oncology Overview","authors":"N. Ibrahim","doi":"10.4172/2376-0419.1000E145","DOIUrl":"https://doi.org/10.4172/2376-0419.1000E145","url":null,"abstract":"The essential feature of the immune system is the ability to recognize and differentiate any foreign body or abnormal cells such as tumor cells from normal cells. Tumor cells produce tumor antigens which activate the immune system. These antigens attract immune cells to the tumor site where they invade and attack. Accordingly, the immune system recognizes the tumor cells and targets them for elimination.","PeriodicalId":16700,"journal":{"name":"Journal of Pharmaceutical Care & Health Systems","volume":"72 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74143116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-07-25DOI: 10.4172/2376-0419.1000179
C. Mwangi, C. Mukanya
Medical non-adherence has been a pervasive issue in healthcare for far too long and consequences of medical non-adherence are far reaching. With the proliferation of mobile technology globally, there have been concerted efforts to improve adherence using mHealth both in developed and developing countries. The objective of this study was to evaluate through previous studies whether mobile phone innovations improve health outcomes through adherence messages to patients and how many of the studies mention and actually consider the content going out to patients as contributing to positive or negative health outcome. A systematic review was conducted using four search engines: PubMed, Mendley, Advanced Google, and Google Scholar. The publications were randomized clinical trials, cross-sectional studies, and pre and post interventional studies. The publications reviewed were considered to be eligible if they were based on use of mobile technology or smart phone applications in improving health outcomes through sending adherence messages. Forty one potential articles were retrieved based on the first search criteria and review of abstracts. Full text was not obtainable for 11 articles due to fees to access the document and/or a registration requirement for the websites making the full text inaccessible. Nine articles were published before the year 2009, 7 were systematic reviews, 1 was an SMS based study but was used by community health workers and did not necessarily address adherence, 3 were protocols for a study to be done, 10 articles met all the inclusion criteria. Mobile health technology has been proven to contribute towards improving adherence to treatment, medication and appointments. However it is crucial to consider the content and its development processes just as much as the technology in use as this might elevate the health outcomes even higher.
{"title":"Does Message-Based Communication Through Mobile Phones for Medication and Treatment Adherence Improve Health Outcomes? A Systematic Review","authors":"C. Mwangi, C. Mukanya","doi":"10.4172/2376-0419.1000179","DOIUrl":"https://doi.org/10.4172/2376-0419.1000179","url":null,"abstract":"Medical non-adherence has been a pervasive issue in healthcare for far too long and consequences of medical non-adherence are far reaching. With the proliferation of mobile technology globally, there have been concerted efforts to improve adherence using mHealth both in developed and developing countries. The objective of this study was to evaluate through previous studies whether mobile phone innovations improve health outcomes through adherence messages to patients and how many of the studies mention and actually consider the content going out to patients as contributing to positive or negative health outcome. A systematic review was conducted using four search engines: PubMed, Mendley, Advanced Google, and Google Scholar. The publications were randomized clinical trials, cross-sectional studies, and pre and post interventional studies. The publications reviewed were considered to be eligible if they were based on use of mobile technology or smart phone applications in improving health outcomes through sending adherence messages. Forty one potential articles were retrieved based on the first search criteria and review of abstracts. Full text was not obtainable for 11 articles due to fees to access the document and/or a registration requirement for the websites making the full text inaccessible. Nine articles were published before the year 2009, 7 were systematic reviews, 1 was an SMS based study but was used by community health workers and did not necessarily address adherence, 3 were protocols for a study to be done, 10 articles met all the inclusion criteria. Mobile health technology has been proven to contribute towards improving adherence to treatment, medication and appointments. However it is crucial to consider the content and its development processes just as much as the technology in use as this might elevate the health outcomes even higher.","PeriodicalId":16700,"journal":{"name":"Journal of Pharmaceutical Care & Health Systems","volume":"20 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2017-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75491079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-07-19DOI: 10.4172/2376-0419.1000178
T. Ahuja, J. Altshuler, J. Papadopoulos
Background: Anticoagulants with renal elimination may accumulate in patients with renal impairment and potentially increase the risk of bleeding. Limited data are available to elucidate the potential bleeding risk present in patients with moderate renal impairment defined as creatinine clearance of 30-50 mL/min. Objective: To evaluate potential risk factors for bleeding over various renal function ranges in patients on enoxaparin, fondaparinux, or dabigatran. Methods: Retrospective chart review from 2010 until 2011 identified patients who incurred a bleeding episode on therapeutic dosed enoxaparin, dabigatran, or fondaparinux stratified according to renal function and presence of pre-defined potential risk factors for bleeding. Bleeding episodes identified using UHC Safety Intelligence, a selfreporting database used to identify safety improvement opportunities. Results: A total of 27 (2.16%) bleeding episodes were identified, 20 occurring during enoxaparin pharmacotherapy and 7 during treatment with dabigatran. There were no fondaparinux bleeds identified. Patients with normal renal function, moderate renal impairment and severe renal impairment incurred 9, 12 and 6 bleeds, respectively. Conclusion: A similar number of patients incurred bleeding episodes on enoxaparin in the normal renal function group and moderate renal impairment group. Patients experiencing bleeding episodes in the enoxaparin group with moderate renal impairment were of advanced age and female. Enoxaparin bleeding episodes were noted in patients with hypertension in all renal function ranges. Patients who bled on dabigatran had some degree of renal impairment and were of advanced age. Concomitant p-glycoprotein inhibitor use was observed in patients with bleeding episodes on dabigatran in patients with renal impairment.
{"title":"Risk Factors for Bleeding Events with Enoxaparin, Dabigatran and Fondaparinux in Hospitalized Patients with Varying Levels of Renal Impairment","authors":"T. Ahuja, J. Altshuler, J. Papadopoulos","doi":"10.4172/2376-0419.1000178","DOIUrl":"https://doi.org/10.4172/2376-0419.1000178","url":null,"abstract":"Background: Anticoagulants with renal elimination may accumulate in patients with renal impairment and potentially increase the risk of bleeding. Limited data are available to elucidate the potential bleeding risk present in patients with moderate renal impairment defined as creatinine clearance of 30-50 mL/min. \u0000Objective: To evaluate potential risk factors for bleeding over various renal function ranges in patients on enoxaparin, fondaparinux, or dabigatran. \u0000Methods: Retrospective chart review from 2010 until 2011 identified patients who incurred a bleeding episode on therapeutic dosed enoxaparin, dabigatran, or fondaparinux stratified according to renal function and presence of pre-defined potential risk factors for bleeding. Bleeding episodes identified using UHC Safety Intelligence, a selfreporting database used to identify safety improvement opportunities. \u0000Results: A total of 27 (2.16%) bleeding episodes were identified, 20 occurring during enoxaparin pharmacotherapy and 7 during treatment with dabigatran. There were no fondaparinux bleeds identified. Patients with normal renal function, moderate renal impairment and severe renal impairment incurred 9, 12 and 6 bleeds, respectively. \u0000Conclusion: A similar number of patients incurred bleeding episodes on enoxaparin in the normal renal function group and moderate renal impairment group. Patients experiencing bleeding episodes in the enoxaparin group with moderate renal impairment were of advanced age and female. Enoxaparin bleeding episodes were noted in patients with hypertension in all renal function ranges. Patients who bled on dabigatran had some degree of renal impairment and were of advanced age. Concomitant p-glycoprotein inhibitor use was observed in patients with bleeding episodes on dabigatran in patients with renal impairment.","PeriodicalId":16700,"journal":{"name":"Journal of Pharmaceutical Care & Health Systems","volume":"10 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2017-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88290923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-07-11DOI: 10.4172/2376-0419.1000177
Fakhrul Hasan, A. A. Noor, Mosiqure Rahman, Kala Chand Debnath, S. Islam
Background: To study the prevalence and prescription pattern for outpatients with neurological disorders in Bangladesh. Methods: The study was conducted on 1684 patients in six hospitals of Dhaka city from March 2014 to June 2015. Data were collected through a predesigned questionnaire from the patients that contain information about sex, age, marital status, occupation, residential status, affected disease, self-medicated drugs and prescribed drugs. Results: Out of 1684 patients, male 963 (57.19%) predominance. The study revealed that headache and migraine 50 (29.75%), stroke 403 (23.93%) and seizure 119 (7.07%) were more projecting neurological disorders. Genetic reason for the neurological disorders was found among only 208 (12.35%) patients. Among 812 patients follow up was reported for 575 (70.82%) patients in which physician follow up was 441 (54.31%) and non-physician follow up was 134 (16.51%) patients. Maximum self-medication usage was found for the period of 3 to 6 months for 247 (41.79%) patients. Disease recovery was satisfactory with the self-medication for 223 (37.73%) patients and 38 (6.43%) patients reported side effects. Most extensively prescribed medicines were multivitamins and multi-minerals 675 (40.08%), NSAIDs and other analgesic 560 (33.25%), antiulcerant 476 (28.27%), anticoagulants 438 (26%), antihyperlipidemic 387 (22.98%) and antiepileptic 305 (18.11%) drugs respectively. The crucial reasons for the selection of prescribed medicines were the confidence with physician’s prescribed drug 690 (40.97%) and knowledge of the drugs 590 (23.99%). The period of prescribed medicines usage was 1 to 3 months for 669 (39.73%) patients and 3 to 6 months for 491 (29.16%) patients. The patient’s compliance for prescribed medicines was satisfactory for 582 (34.56%) patients, good for 474 (28.15%) patients and side effect was reported for 391 (23.22%) patients. Conclusion: In Bangladesh neurological diseases are not surprising rather than other different diseases prevail in different age and sex. Headache and migraine, stroke and seizure are most frequently encountered neurological disorders here. Treatment procedure of these disorders is not quite suitable due to the anomalies of healthcare management system. Appropriate management of the healthcare system can overcome the existing inconsistencies as well as increase the knowledge, awareness and perception of the patients about health and disorders.
{"title":"Disease and Prescription Pattern for Outpatients with NeurologicalDisorders in Bangladesh: An Empirical Pilot Study","authors":"Fakhrul Hasan, A. A. Noor, Mosiqure Rahman, Kala Chand Debnath, S. Islam","doi":"10.4172/2376-0419.1000177","DOIUrl":"https://doi.org/10.4172/2376-0419.1000177","url":null,"abstract":"Background: To study the prevalence and prescription pattern for outpatients with neurological disorders in Bangladesh. \u0000Methods: The study was conducted on 1684 patients in six hospitals of Dhaka city from March 2014 to June 2015. Data were collected through a predesigned questionnaire from the patients that contain information about sex, age, marital status, occupation, residential status, affected disease, self-medicated drugs and prescribed drugs. \u0000Results: Out of 1684 patients, male 963 (57.19%) predominance. The study revealed that headache and migraine 50 (29.75%), stroke 403 (23.93%) and seizure 119 (7.07%) were more projecting neurological disorders. Genetic reason for the neurological disorders was found among only 208 (12.35%) patients. Among 812 patients follow up was reported for 575 (70.82%) patients in which physician follow up was 441 (54.31%) and non-physician follow up was 134 (16.51%) patients. Maximum self-medication usage was found for the period of 3 to 6 months for 247 (41.79%) patients. Disease recovery was satisfactory with the self-medication for 223 (37.73%) patients and 38 (6.43%) patients reported side effects. Most extensively prescribed medicines were multivitamins and multi-minerals 675 (40.08%), NSAIDs and other analgesic 560 (33.25%), antiulcerant 476 (28.27%), anticoagulants 438 (26%), antihyperlipidemic 387 (22.98%) and antiepileptic 305 (18.11%) drugs respectively. The crucial reasons for the selection of prescribed medicines were the confidence with physician’s prescribed drug 690 (40.97%) and knowledge of the drugs 590 (23.99%). The period of prescribed medicines usage was 1 to 3 months for 669 (39.73%) patients and 3 to 6 months for 491 (29.16%) patients. The patient’s compliance for prescribed medicines was satisfactory for 582 (34.56%) patients, good for 474 (28.15%) patients and side effect was reported for 391 (23.22%) patients. \u0000Conclusion: In Bangladesh neurological diseases are not surprising rather than other different diseases prevail in different age and sex. Headache and migraine, stroke and seizure are most frequently encountered neurological disorders here. Treatment procedure of these disorders is not quite suitable due to the anomalies of healthcare management system. Appropriate management of the healthcare system can overcome the existing inconsistencies as well as increase the knowledge, awareness and perception of the patients about health and disorders.","PeriodicalId":16700,"journal":{"name":"Journal of Pharmaceutical Care & Health Systems","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82440377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-22DOI: 10.4172/2376-0419.1000176
P. Tiwari, N. Sharma
Vitamin D, a fat-soluble vitamin, concentrations need to be maintained for functioning of the metabolic, immune, reproductive, muscular, skeletal, respiratory and cutaneous systems of men and women of all ages. A rough estimate indicates that about 1 billion people globally are vitamin D deficient. The physiological functions of active vitamin D (calcitriol) are related to calcium homeostasis and osteoporosis, with possible roles in diabetes, cancer, ischemic heart disease, and autoimmune and infectious diseases. Vitamin D deficit increases the risk of malignancies, particularly of colon, breast and prostate gland, of chronic inflammatory and autoimmune diseases (e.g. insulin-dependent diabetes mellitus, inflammatory bowel disease, multiple sclerosis), as well as of metabolic disorders (metabolic syndrome, hypertension). The eight disorders discussed in this review are heart disease, bone disorder, colorectal cancer and other malignancies, infectious, inflammatory and autoimmune diseases, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and type-I diabetes mellitus. There is a strong evidence for association between heart diseases, bone disorders, colorectal cancers, infectious, inflammatory and autoimmune diseases, inflammatory bowel diseases, multiple sclerosis, diabetes mellitus type-I and vitamin D. the extent of vitamin D deficiency’s contribution in the development of osteoporosis, breast cancer, rheumatoid arthritis is unclear.
{"title":"Role of Vitamin D in Various Illnesses: A Review","authors":"P. Tiwari, N. Sharma","doi":"10.4172/2376-0419.1000176","DOIUrl":"https://doi.org/10.4172/2376-0419.1000176","url":null,"abstract":"Vitamin D, a fat-soluble vitamin, concentrations need to be maintained for functioning of the metabolic, immune, reproductive, muscular, skeletal, respiratory and cutaneous systems of men and women of all ages. A rough estimate indicates that about 1 billion people globally are vitamin D deficient. The physiological functions of active vitamin D (calcitriol) are related to calcium homeostasis and osteoporosis, with possible roles in diabetes, cancer, ischemic heart disease, and autoimmune and infectious diseases. Vitamin D deficit increases the risk of malignancies, particularly of colon, breast and prostate gland, of chronic inflammatory and autoimmune diseases (e.g. insulin-dependent diabetes mellitus, inflammatory bowel disease, multiple sclerosis), as well as of metabolic disorders (metabolic syndrome, hypertension). The eight disorders discussed in this review are heart disease, bone disorder, colorectal cancer and other malignancies, infectious, inflammatory and autoimmune diseases, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and type-I diabetes mellitus. There is a strong evidence for association between heart diseases, bone disorders, colorectal cancers, infectious, inflammatory and autoimmune diseases, inflammatory bowel diseases, multiple sclerosis, diabetes mellitus type-I and vitamin D. the extent of vitamin D deficiency’s contribution in the development of osteoporosis, breast cancer, rheumatoid arthritis is unclear.","PeriodicalId":16700,"journal":{"name":"Journal of Pharmaceutical Care & Health Systems","volume":"1 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2017-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91198109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-04-29DOI: 10.4172/2376-0419.1000175
K. Datta, K. Rahalkar, Dinesh Dk
For the reason that no model will ever totally replicate clinical human wound healing, it is necessary that the model operated be selected with care. Heat Shock Proteins (Hsp) is articulated in response to numerous biological stresses, comprising heat, high pressures, and toxic composites. It is also one of the mainly bountiful cellular proteins found under non-stress situation. Hsp70 and Hsp90 refer to families of heat shock proteins on the order of 70, 90 kilo Daltons in size, respectively. The small 8 kD protein ubiquitin, which marks proteins for degradation, also has features of a heat shock protein. Cells are attentive about getting these folds right for the reason that mis-folded proteins can change the normal life of the cell. In some cases change is good, in others deadly. When Heat Shock Proteins 90 is conceded the number of morphological alterations upsurges, which lead to creation of inactive or abnormally active polypeptides.
{"title":"Heat Shock Proteins (Hsp): Classifications and Its Involvement in Health and Disease","authors":"K. Datta, K. Rahalkar, Dinesh Dk","doi":"10.4172/2376-0419.1000175","DOIUrl":"https://doi.org/10.4172/2376-0419.1000175","url":null,"abstract":"For the reason that no model will ever totally replicate clinical human wound healing, it is necessary that the model operated be selected with care. Heat Shock Proteins (Hsp) is articulated in response to numerous biological stresses, comprising heat, high pressures, and toxic composites. It is also one of the mainly bountiful cellular proteins found under non-stress situation. Hsp70 and Hsp90 refer to families of heat shock proteins on the order of 70, 90 kilo Daltons in size, respectively. The small 8 kD protein ubiquitin, which marks proteins for degradation, also has features of a heat shock protein. Cells are attentive about getting these folds right for the reason that mis-folded proteins can change the normal life of the cell. In some cases change is good, in others deadly. When Heat Shock Proteins 90 is conceded the number of morphological alterations upsurges, which lead to creation of inactive or abnormally active polypeptides.","PeriodicalId":16700,"journal":{"name":"Journal of Pharmaceutical Care & Health Systems","volume":"36 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2017-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85452565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-04-28DOI: 10.4172/2376-0419.1000174
M. Hajiesmaeili, G. Afzal, Z. Sahraei
Polypharmacy-induced QT prolongation is a possible hazardous adverse effect of several medication combinations. When QT prolongation leads to torsade de pointes, life-threatening or mortal outcomes can result. A 45-year-old man presented to the emergency department due to the use of methadone in the field with ventricular tachycardia and after successful resuscitation after cardiac arrest, under ICU care, has been exacerbated torsade de point due to polypharmacy with high-dose methadone, the patient had multiple risk factors for prolonged QT syndrome including methadone therapy, multiple drug therapy leading to potential drug interactions, electrolyte disturbances such as hypomagnesaemia. Clinical pharmacy must be aware of multidrug interactions potentiating QT prolongation and leading to torsade de pointes. In this article has emphasized the importance of considering the cumulative effects of several drugs used in the ICU and their timely treatment and possible avoidance of poly pharmacy.
{"title":"Poly Pharmacy-Induced Long-QT Syndrome and Torsades de Pointes: A Case Report","authors":"M. Hajiesmaeili, G. Afzal, Z. Sahraei","doi":"10.4172/2376-0419.1000174","DOIUrl":"https://doi.org/10.4172/2376-0419.1000174","url":null,"abstract":"Polypharmacy-induced QT prolongation is a possible hazardous adverse effect of several medication combinations. When QT prolongation leads to torsade de pointes, life-threatening or mortal outcomes can result. A 45-year-old man presented to the emergency department due to the use of methadone in the field with ventricular tachycardia and after successful resuscitation after cardiac arrest, under ICU care, has been exacerbated torsade de point due to polypharmacy with high-dose methadone, the patient had multiple risk factors for prolonged QT syndrome including methadone therapy, multiple drug therapy leading to potential drug interactions, electrolyte disturbances such as hypomagnesaemia. Clinical pharmacy must be aware of multidrug interactions potentiating QT prolongation and leading to torsade de pointes. In this article has emphasized the importance of considering the cumulative effects of several drugs used in the ICU and their timely treatment and possible avoidance of poly pharmacy.","PeriodicalId":16700,"journal":{"name":"Journal of Pharmaceutical Care & Health Systems","volume":"7 6 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87258184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-04-28DOI: 10.4172/2376-0419.1000173
Y. Yiqing
{"title":"Gut Microbiota: What We Could Do, Not Just Use âÂÂYoung Healthy PooâÂÂfor Drugs?","authors":"Y. Yiqing","doi":"10.4172/2376-0419.1000173","DOIUrl":"https://doi.org/10.4172/2376-0419.1000173","url":null,"abstract":"","PeriodicalId":16700,"journal":{"name":"Journal of Pharmaceutical Care & Health Systems","volume":"17 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2017-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87851126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-04-21DOI: 10.4172/2376-0419.1000172
S. Thakur, Pramod Ks, R. Malviya
Rapid advancement in medicine and biotechnology has driven the field of drug discovery. Novel approaches of drug delivery such as formulating the polymeric nanoparticles is revolutionizing the future of medicines. Newly potent and target specific drugs led to enhance therapeutic utility. These challenges, coupled with the complexity and variety, are fueling the advancement of novel drug delivery systems that overcome bioavailability and delivery obstacles. In present scenario, nanoparticles have been acting as carriers for delivering a wide range of potential drugs. Due to their versatility and wide range of properties and they represent a promising drug delivery system of controlled and targeted release. The utilization of polymeric nanoparticles is a plan that aims to minimize adverse effect and will optimize therapeutic effects. Nanoparticle-based therapy facilitates safe and efficacious therapy for cancer patients. Advancement in Nanomedicine technologies provides clear evidence that polymeric nanotherapies have a significant impact in oncology. Improvement in therapeutic utility of polymeric nano-particulate system is highlighted in this paper. This review deals with the polymeric nanoparticulate systems, fate of nanoparticles, its types, targetting mechanism, application and recent patents.
{"title":"Utilization of Polymeric Nanoparticle in Cancer Treatment: A Review","authors":"S. Thakur, Pramod Ks, R. Malviya","doi":"10.4172/2376-0419.1000172","DOIUrl":"https://doi.org/10.4172/2376-0419.1000172","url":null,"abstract":"Rapid advancement in medicine and biotechnology has driven the field of drug discovery. Novel approaches of drug delivery such as formulating the polymeric nanoparticles is revolutionizing the future of medicines. Newly potent and target specific drugs led to enhance therapeutic utility. These challenges, coupled with the complexity and variety, are fueling the advancement of novel drug delivery systems that overcome bioavailability and delivery obstacles. In present scenario, nanoparticles have been acting as carriers for delivering a wide range of potential drugs. Due to their versatility and wide range of properties and they represent a promising drug delivery system of controlled and targeted release. The utilization of polymeric nanoparticles is a plan that aims to minimize adverse effect and will optimize therapeutic effects. Nanoparticle-based therapy facilitates safe and efficacious therapy for cancer patients. Advancement in Nanomedicine technologies provides clear evidence that polymeric nanotherapies have a significant impact in oncology. Improvement in therapeutic utility of polymeric nano-particulate system is highlighted in this paper. This review deals with the polymeric nanoparticulate systems, fate of nanoparticles, its types, targetting mechanism, application and recent patents.","PeriodicalId":16700,"journal":{"name":"Journal of Pharmaceutical Care & Health Systems","volume":"32 1","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2017-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81517949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-04-14DOI: 10.4172/2376-0419.1000E144
Aisha Morris Moultry
In this political climate and era of highly debated healthcare, it is more important than ever to be involved in advocacy for the profession. When the Medicare Modernization Act (MMA) passed in 2003 and subsequently the Patient Protection and Affordable Care Act (PPACA) in 2010, pharmacists saw an opportunity to gain provider status. However, the profession encountered barriers in the area of reimbursement. Thus, it is important that pharmacists have a presence when decisions are being made about the profession. A proven and successful avenue to pursue this is advocacy. Advocacy is defined as the act or process of supporting a cause or proposal [1]. Although political advocacy through a presence at the local state capitol or Washington, D.C. tends to be the type of advocacy that immediately comes to mind, other methods for promoting the profession can occur in the form of promotion in the community with patients and other practitioners or in an academic setting to future professionals.
{"title":"Advocating for Pharmacy: What Can You Do?","authors":"Aisha Morris Moultry","doi":"10.4172/2376-0419.1000E144","DOIUrl":"https://doi.org/10.4172/2376-0419.1000E144","url":null,"abstract":"In this political climate and era of highly debated healthcare, it is more important than ever to be involved in advocacy for the profession. When the Medicare Modernization Act (MMA) passed in 2003 and subsequently the Patient Protection and Affordable Care Act (PPACA) in 2010, pharmacists saw an opportunity to gain provider status. However, the profession encountered barriers in the area of reimbursement. Thus, it is important that pharmacists have a presence when decisions are being made about the profession. A proven and successful avenue to pursue this is advocacy. Advocacy is defined as the act or process of supporting a cause or proposal [1]. Although political advocacy through a presence at the local state capitol or Washington, D.C. tends to be the type of advocacy that immediately comes to mind, other methods for promoting the profession can occur in the form of promotion in the community with patients and other practitioners or in an academic setting to future professionals.","PeriodicalId":16700,"journal":{"name":"Journal of Pharmaceutical Care & Health Systems","volume":"61 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2017-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84659704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：